Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Par, Intellipharmaceutics Expand ADHD Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Par, Intellipharmaceutics Expand ADHD Pact

Will include additional strengths of generic Focalin for U.S. market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Intellipharmaceutics International Inc. and Par Pharmaceutical, Inc. have added the development and commercialization of additional strengths of generic Focalin XR (dexmethylphenidate hydrochloride) for the U.S. market to their existing agreement, which includes 5, 10, 15 and 20mg strengths of generic Focalin XR.

Intellipharmaceutics will receive an immediate cash payment from Par and will continue to receive a share of sales profits. Focalin XR is used in the treatment of Attention Deficit Hyperactivity Disorder. Sales in the U.S. were approximately $536 million for the year ending June 2011.

Intellipharmaceutics has five strengths (5, 10, 15, 20 and 30mg) of the generic Focalin XR pending with the FDA. Intellipharmaceutics and Par are involved in a settlement of their earlier U.S. litigation against Novartis Pharmaceuticals Corp., Elan Pharma International Ltd., and Celgene Corp. for the 5, 10, 15, and 20mg products. Intellipharmaceutics and Par are currently defendants in on-going U.S. litigation against the same plaintiffs for the 30 mg product.

“We are extremely pleased with the expansion of the agreement we currently have in place with Par for the development and commercialization of generic Focalin XR,” said Dr. Isa Odidi, chief executive officer of Intellipharmaceutics. “This adds further credibility to the quality of our work and the growth of our company.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters